🏛️ Verified NIH Record • Updated 2025-09-30
Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT) (NCT05878184)
A Phase 1 Study Evaluating SC291, a Hypoimmune, Allogeneic CD19-directed CAR T Cell Therapy, in Relapsed and/or Refractory B-cell Malignancies (ARDENT)
🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic Sponsor: Sana Biotechnology
🩺 Plain-English Summary (8th-Grade Level)
SC291-101 is a Phase 1 study to evaluate SC291 safety and tolerability, anti-tumor activity, cellular kinetics, immunogenicity, and exploratory biomarkers.
Who can join: Review the eligibility criteria below.
Location: City of Hope — Duarte, California
Age range: 18 Years to 80 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (10 Sites)
- City of Hope — Duarte, California
- Stanford Cancer Institute — Palo Alto, California
- Northside Hospital — Atlanta, Georgia
- University of Kansas Medical Center — Fairway, Kansas
- Karmanos Cancer Institute — Detroit, Michigan
- University of Nebraska Medical Center — Omaha, Nebraska
- MD Anderson Cancer Center — Houston, Texas
- Royal Adelaide Hospital — Adelaide, South Australia
- Peter MacCallum Cancer Centre — Melbourne, Victoria
- Linear Clinical Research Ltd — Nedlands, Western Australia
📞 Contact the Study Coordinator
Phone: (800) 826-4673
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Non Hodgkin Lymphoma
- Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma — Tucson, Arizona
- TmCD19-IL18 in CD19+ Cancers — Philadelphia, Pennsylvania
- Intrathecal Rituximab With Standard Intrathecal Prophylaxis to Prevent CNS Relapse for CD 20+ Non Hodgkin Lymphoma — Cincinnati, Ohio
- Evaluate the Safety of UF-KURE19 Cells in Non-Hodgkin Lymphomas — Iowa City, Iowa
- Human AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Lymphoid Malignancies — Cleveland, Ohio
Explore by condition: All Non Hodgkin Lymphoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.